399 related articles for article (PubMed ID: 16784923)
1. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
Huptas S; Geiss HC; Otto C; Parhofer KG
Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
[TBL] [Abstract][Full Text] [Related]
2. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
3. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
4. Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus.
Amudha K; Choy AM; Mustafa MR; Lang CC
Cardiovasc Ther; 2008; 26(4):253-61. PubMed ID: 19035876
[TBL] [Abstract][Full Text] [Related]
5. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
Stalenhoef AF; Ballantyne CM; Sarti C; Murin J; Tonstad S; Rose H; Wilpshaar W
Eur Heart J; 2005 Dec; 26(24):2664-72. PubMed ID: 16143705
[TBL] [Abstract][Full Text] [Related]
6. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
Leiter LA; Martineau P; de Teresa E; Farsang C; Gaw A; Gensini G; Langer A;
J Fam Pract; 2008 Oct; 57(10):661-8. PubMed ID: 18842192
[TBL] [Abstract][Full Text] [Related]
7. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
8. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.
Anagnostis P; Selalmatzidou D; Polyzos SA; Panagiotou A; Slavakis A; Panagiotidou A; Athyros VG; Karagiannis A; Mikhailidis DP; Kita M
Int J Clin Pract; 2011 Jun; 65(6):679-83. PubMed ID: 21564441
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin prevents type 2 diabetes mellitus--an experimental study.
Madhu SV; Aslam M; Galav V; Bhattacharya SK; Jafri AA
Eur J Pharmacol; 2014 Apr; 728():135-40. PubMed ID: 24530420
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
12. The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in subjects with the metabolic syndrome.
Snel M; Sleddering MA; Pijl H; Nieuwenhuizen WF; Frölich M; Havekes LM; Romijn JA; Jazet IM
Eur J Clin Nutr; 2010 Apr; 64(4):419-23. PubMed ID: 20179727
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
[TBL] [Abstract][Full Text] [Related]
14. Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.
Mehta A; Shah U; Parikh K; Chag M; Baxi H; Chandarana A; Naik A; Naik A; Shah K; Goyal R
Can J Physiol Pharmacol; 2007 Jun; 85(6):628-33. PubMed ID: 17823625
[TBL] [Abstract][Full Text] [Related]
15. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
[TBL] [Abstract][Full Text] [Related]
16. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Betteridge DJ; Gibson JM
Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
[TBL] [Abstract][Full Text] [Related]
18. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
[TBL] [Abstract][Full Text] [Related]
19. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.
Nagel JM; Tietz AB; Göke B; Parhofer KG
Metabolism; 2006 Sep; 55(9):1149-54. PubMed ID: 16919531
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Betteridge DJ; Gibson JM; Sager PT
Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
